Brief: Hikma Expands Licensing Agreement With Celltrion For Remsima Subcutaneous Formulation In MENA
07/02/2022 13:34
Feb 7 (Reuters) - Hikma Pharmaceuticals PLC:
* HIKMA - EXPANDS LICENSING AGREEMENT WITH CELLTRION FOR
REMSIMA
SUBCUTANEOUS FORMULATION IN MENA
Source text for Eikon: ID:
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won